Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Williams-Sonoma, Inc. — how do they compare? Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $127.55B), while Williams-Sonoma, Inc. trades at $239 (market cap $28.15B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 4.5× Williams-Sonoma, Inc.'s market cap, and Williams-Sonoma, Inc. pays a 1.27% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vertex Pharmaceuticals Incorporated for 120 Days and Williams-Sonoma, Inc. for 59 Days on average.
| VRTX | WSM | |
|---|---|---|
Market Cap | $127.55B | $28.15B |
Volume | 1,487,944 | 1,351,262 |
Sector | Health | Consumer Cyclical |
52-Week High | $557.96 | $251.81 |
52-Week Low | $407.37 | $168.64 |
Typical Hold Time | 120 Days | 59 Days |
Enterprise Value | $121.68B | $28.65B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
Williams-Sonoma (WSM) trades at $240.46, down 0.74% on the day, with a bullish technical signal and strong profitability metrics. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Recent news highlights market share gains, margin expansion, and new store openings, reinforcing positive business momentum.
The outlook remains favorable given earnings outperformance and raised guidance, though valuation multiples are elevated. Key risks include housing market sensitivity and competitive pressures. Analyst consensus is mixed but leans positive, with a price target suggesting modest upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
